 | ||
Register here to receive the On Demand Archive
|
Speakers for this Event:
|
Sponsored by:
|
The traditional CRO-Sponsor relationship is coming to an inflection point. As the drug development and outsourcing industries continue to mature and as cost pressures continue to increase, progressive players are starting to look for more value in their relationships.
In this webinar Tim Dietlin, VP of Alliance Development, INC Research, and David Gillogly, Global Head, Clinical Contracting and Category Management, Novartis will explore what clinical delivery alliances are and the value alliance partnership models bring to the drug development process from both the sponsor and CRO perspective. Our presenters will discuss:
- How do more strategic relationships positively affect performance and outcomes
- When do alliance partnerships make sense for a sponsor or a CRO
- What alliance partnership models are emerging, such as risk sharing, value-based pricing, bonus-malus, dedicated governance, deferred payments, etc.
- Lessons learned from current clinical delivery alliance models – what works and what doesn’t
- How both large pharma and biotechs can benefit from creative partnership structures and a process driven methodology for managing strategic development programs
Access to this archive is given on the understanding that you agree to the provision of your contact information to Xtalks sponsors and partners. Only primary contact information will be shared and this information will only be shared for the purposes of providing relevant offers. This registration form is an application only. Xtalks has the right to refuse access.
If you require help with your registration or have any questions you may contact Xtalks at: email: register@xtalks.com; phone: 416-977-6555, x 371.
By completing this registration form, you agree that the information you have provided is true and accurate.
(note: fields with marked "*" are required)